Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CROWD feasibility trial of surgery after chemoradiotherapy followed by durvalumab in stage III non-small cell lung cancer
NL-OMON60424Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Safety of surgery and Ability to proceed to durvalumab consolidation after surgery. Started Dec 2024; status: recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60424.